Analysis of the optimal psoas muscle mass index cut-off values, as measured by computed tomography, for the diagnosis of loss of skeletal muscle mass in Japanese people.
liver disease
psoas muscle
sarcopenia
skeletal muscle
Journal
Hepatology research : the official journal of the Japan Society of Hepatology
ISSN: 1386-6346
Titre abrégé: Hepatol Res
Pays: Netherlands
ID NLM: 9711801
Informations de publication
Date de publication:
Jun 2020
Jun 2020
Historique:
received:
18
10
2019
revised:
02
02
2020
accepted:
18
03
2020
pubmed:
24
3
2020
medline:
24
3
2020
entrez:
24
3
2020
Statut:
ppublish
Résumé
This study aimed to determine the optimal psoas muscle mass index (PMI) cut-off values for diagnosis of skeletal muscle mass loss. We evaluated PMI in two groups of normal controls: a medical check-up group and a liver donation candidate group. We analyzed two novel PMI cut-off values, one based on the mean - two standard deviations (2SD) and one based on the lower 5%. Skeletal muscle mass index (SMI) evaluations using computed tomography (sliceOmatic; TomoVision) and bioelectrical impedance analysis and PMI evaluation were undertaken simultaneously. We analyzed the correlation between our PMI cut-off values and the Japan Society of Hepatology-defined SMI cut-off values. The prevalence of skeletal muscle mass loss in patients with liver disease was assessed using the novel PMI cut-off values. In 504 normal controls aged ≤50 years, the PMI cut-off values based on mean -2SD and the lower 5% were set at 3.30 cm We propose the following PMI cut-off values: 3.74 cm
Types de publication
Journal Article
Langues
eng
Pagination
715-725Subventions
Organisme : Japan Agency for Medical Research and Development
ID : 19fk0210022h0103, 19fk0210018h0003
Organisme : Japan Agency for Medical Research and Development
ID : 19fk0210058h0001, 19fk0210047s0401
Organisme : Japan Agency for Medical Research and Development
ID : 19fk0310101s0503, 19fk0210048s0501
Organisme : KAKENHI
ID : Grant Number 19K08458
Informations de copyright
© 2020 The Japan Society of Hepatology.
Références
Cruz-Jentoft AJ, Landi F, Schneider SM et al. Prevalence of and interventions for sarcopenia in ageing adults: a systematic review. Report of the International Sarcopenia Initiative (EWGSOP and IWGS). Age Ageing 2014; 43: 748-759.
Marcell TJ. Sarcopenia: causes, consequences, and preventions. J Gerontol A Biol Sci Med Sci 2003; 58: M911-M916.
Cruz-Jentoft AJ, Baeyens JP, Bauer JM et al. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age Ageing 2010; 39: 412-423.
Sousa-Victor P, Munoz-Canoves P. Regenerative decline of stem cells in sarcopenia. Mol Aspects Med 2016; 50: 109-117.
Blau HM, Cosgrove BD, Ho AT. The central role of muscle stem cells in regenerative failure with aging. Nat Med 2015; 21: 854-862.
Dasarathy S. Consilience in sarcopenia of cirrhosis. J Cachexia Sarcopenia Muscle 2012; 3: 225-237.
Hanai T, Shiraki M, Ohnishi S et al. Rapid skeletal muscle wasting predicts worse survival in patients with liver cirrhosis. Hepatol Res 2016; 46: 743-751.
Iritani S, Imai K, Takai K et al. Skeletal muscle depletion is an independent prognostic factor for hepatocellular carcinoma. J Gastroenterol 2015; 50: 323-332.
Masuda T, Shirabe K, Ikegami T et al. Sarcopenia is a prognostic factor in living donor liver transplantation. Liver Transpl 2014; 20: 401-407.
Cruz-Jentoft AJ, Bahat G, Bauer J et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing 2019; 48: 16-31.
Chen LK, Liu LK, Woo J et al. Sarcopenia in Asia: consensus report of the Asian Working Group for Sarcopenia. J Am Med Dir Assoc 2014; 15: 95-101.
Nishikawa H, Shiraki M, Hiramatsu A, Moriya K, Hino K, Nishiguchi S. Japan Society of Hepatology guidelines for sarcopenia in liver disease (1st edition): recommendation from the working group for creation of sarcopenia assessment criteria. Hepatol Res 2016; 46: 951-963.
Pirlich M, Schutz T, Spachos T et al. Bioelectrical impedance analysis is a useful bedside technique to assess malnutrition in cirrhotic patients with and without ascites. Hepatology 2000; 32: 1208-1215.
Ohara M, Ogawa K, Suda G et al. L-carnitine suppresses loss of skeletal muscle mass in patients with liver cirrhosis. Hepatol Commun 2018; 2: 906-918.
Hamaguchi Y, Kaido T, Okumura S et al. Impact of quality as well as quantity of skeletal muscle on outcomes after liver transplantation. Liver Transpl 2014; 20: 1413-1419.
Hiraoka A, Izumoto H, Ueki H et al. Easy surveillance of muscle volume decline in chronic liver disease patients using finger-circle (yubi-wakka) test. J Cachexia Sarcopenia Muscle 2019; 10: 347-354.
Hiraoka A, Michitaka K, Izumoto H et al. Relative changes in handgrip strength and skeletal muscle volume in patients with chronic liver disease over a 2-year observation period. Hepatol Res 2018; 48: 502-508.
Hamaguchi Y, Kaido T, Okumura S et al. Proposal for new diagnostic criteria for low skeletal muscle mass based on computed tomography imaging in Asian adults. Nutrition 2016; 32: 1200-1205.
Hiraoka A, Aibiki T, Okudaira T et al. Muscle atrophy as pre-sarcopenia in Japanese patients with chronic liver disease: computed tomography is useful for evaluation. J Gastroenterol 2015; 50: 1206-1213.
Baumgartner RN, Koehler KM, Gallagher D et al. Epidemiology of sarcopenia among the elderly in New Mexico. Am J Epidemiol 1998; 147: 755-763.
Assy N, Hochberg Z, Amit T, Shen-Orr Z, Enat R, Baruch Y. Growth hormone-stimulated insulin-like growth factor (IGF) I and IGF-binding protein-3 in liver cirrhosis. J Hepatol 1997; 27: 796-802.
Kitson MT, Roberts SK. D-livering the message: the importance of vitamin D status in chronic liver disease. J Hepatol 2012; 57: 897-909.
Katsanos CS, Kobayashi H, Sheffield-Moore M, Aarsland A, Wolfe RR. A high proportion of leucine is required for optimal stimulation of the rate of muscle protein synthesis by essential amino acids in the elderly. Am J Physiol Endocrinol Metab 2006 Aug; 291: E381-7.
Borsheim E, Bui QU, Tissier S, Kobayashi H, Ferrando AA, Wolfe RR. Effect of amino acid supplementation on muscle mass, strength and physical function in elderly. Clin Nutr 2008; 27: 189-195.
Moriwaki H, Miwa Y, Tajika M, Kato M, Fukushima H, Shiraki M. Branched-chain amino acids as a protein- and energy-source in liver cirrhosis. Biochem Biophys Res Commun 2004; 313: 405-409.
Harimoto N, Yoshizumi T, Shimokawa M et al. Sarcopenia is a poor prognostic factor following hepatic resection in patients aged 70 years and older with hepatocellular carcinoma. Hepatol Res 2016; 46: 1247-1255.
Higashi T, Hayashi H, Taki K et al. Sarcopenia, but not visceral fat amount, is a risk factor of postoperative complications after major hepatectomy. Int J Clin Oncol 2016 Apr; 21: 310-319.
Kamachi S, Mizuta T, Otsuka T et al. Sarcopenia is a risk factor for the recurrence of hepatocellular carcinoma after curative treatment. Hepatol Res 2016; 46: 201-208.
Hanai T, Shiraki M, Nishimura K et al. Sarcopenia impairs prognosis of patients with liver cirrhosis. Nutrition 2015; 31: 193-199.
Ceniccola GD, Castro MG, Piovacari SMF et al. Current technologies in body composition assessment: advantages and disadvantages. Nutrition 2018; 62: 25-31.
Beaudart C, McCloskey E, Bruyere O et al. Sarcopenia in daily practice: assessment and management. BMC Geriatr 2016; 16: 170.